Biomaterial Database

Prazosin in the treatment of patients with hypertension and renal functional impairment. 1977

R R Bailey

Prazosin was used as an additional antihypertensive agent for treating 38 patients with hypertension and renal functional impairment. The drug was effective in 29 of these patients at a mean daily dose of 7 mg. The mean blood pressure fall in these 29 patients was 28/22 mm Hg. The most frequent (10 patients) and important side effect of prazosin treatment was dizziness, which occurred on standing of after exertion and was seen either after the first dose or after a large dose increase. The "first-dose phenomenon" was a result of severe postural hypotension and was eliminated by using a starting dose of 0-5 mg every 12 hours, with the first dose being given before retiring to bed. Dosage increments were limited to 0-5 mg, beginning late in the evening. Eleven patients had a significant improvement in renal function, while a further eight patients had stable renal function. In no patient was there a deterioration in renal function which could be attributed to prazosin.

UI	MeSH Term	Description	Entries
D006977	Hypertension, Renal	Persistent high BLOOD PRESSURE due to KIDNEY DISEASES, such as those involving the renal parenchyma, the renal vasculature, or tumors that secrete RENIN.	Hypertensions, Renal,Renal Hypertension,Renal Hypertensions
D007676	Kidney Failure, Chronic	The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.	ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297	Male		Males
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D011224	Prazosin	A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.	Furazosin,Minipress,Pratsiol,Prazosin HCL,Prazosin Hydrochloride,HCL, Prazosin,Hydrochloride, Prazosin
D011799	Quinazolines	A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.	Quinazoline
D005260	Female		Females
D005919	Glomerular Filtration Rate	The volume of water filtered out of plasma through glomerular capillary walls into Bowman's capsules per unit of time. It is considered to be equivalent to INULIN clearance.	Filtration Rate, Glomerular,Filtration Rates, Glomerular,Glomerular Filtration Rates,Rate, Glomerular Filtration,Rates, Glomerular Filtration
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013268	Stimulation, Chemical	The increase in a measurable parameter of a PHYSIOLOGICAL PROCESS, including cellular, microbial, and plant; immunological, cardiovascular, respiratory, reproductive, urinary, digestive, neural, musculoskeletal, ocular, and skin physiological processes; or METABOLIC PROCESS, including enzymatic and other pharmacological processes, by a drug or other chemical.	Chemical Stimulation,Chemical Stimulations,Stimulations, Chemical